Skip to main navigation or content
Meldex’s shares fell as much as 19 per cent after 2007's revenues failed to match those indicated in its trading update in late January. Moreover, the group's pre-tax profit (adjusted for such items as amortisation and exceptionals) reached just £1.6m - well below broker Landsbanki's £3.8m forecast.
Advertising
Shareholders shouldn't, however, be too alarmed as the difference reflects accounting issues. Essentially, International Financial Reporting Standards doesn't allow for the inclusion of two group products - Rocgel and Alfatil - that were acquired during the year, says management. The good news for shareholders, according to chief executive Richard Trevillion, is that this will be overlooked by the potential bidders that the company has been in discussions with since the beginning of the year.
No further details about the timing of that process were were provided, but management remains upbeat about the trading outlook. Indeed, the company has 155 medical products being sold in various markets around the world with several due for launch this year and next. Moreover, Meldex's acquisition of the Melbrosin group of companies during the year has made a significant contribution to the business and helped the group to penetrate new markets.
| MELDEX INTERNATIONAL (MDX) | ||||
|---|---|---|---|---|
| ORD PRICE: | 51p | MARKET VALUE: | £ 109.1m | |
| TOUCH: | 51-52p | 12-MONTH HIGH: | 97p | LOW: 37p |
| DIVIDEND YIELD: | NIL | PE RATIO: | 85 | |
| NET ASSET VALUE: | 33p* | NET DEBT: | 5% | |
| Year to 31 Dec | Turnover (£m) | Pre-tax profit (£m) | Earnings per share (p) | Dividend per share (p) |
|---|---|---|---|---|
| 2003 | 0.95 | -1.67 | -3.40 | nil |
| 2004 | 2.51 | -7.13 | -6.30 | nil |
| 2005 | 4.40 | -9.07 | -7.50 | nil |
| 2006 | 9.47 | -1.94 | -1.20 | nil |
| 2007 | 27.1 | -0.35 | 0.60 | nil |
| % change | +187 | - | - | - |
*Includes intangible assets of £75m, or 35p a share |
||||
Click here for a guide to the terms used in IC results tables.
Meldex's shares are amongst the more volatile in the sector, and are currently below our buy advice (60p, 31 December 2007). Still, the decent business model looks set to deliver earnings growth of over 20 per cent a year, while a potential bid could also mean more upside. Buy.
Last IC View: Buy, 70p, 17 March 2008
The UK’s No.1 Stockbroker
Access a selection of share tips, comprehensive company analysis and full financial data on listed companies. Plus portfolio tools with advanced alerts when you register for free here.
Advertorial Feature
With so many big moves in the world's financial markets, there have seldom been more opportunities around for spread traders. Isn't it time you joined them?
by Dominic Piccarda
© The Financial Times Limited 2008. All rights reserved. "Investors Chronicle", "FT" and "Financial Times" are trademarks of The Financial Times Limited. No part of these web pages may be reproduced or transmitted to or stored in any other website or other form of electronic retrieval system, without prior permission in writing from the editor.
Warning: Do remember, particularly if you are new to stock market investment that the prices of shares and other investments can fall sharply. You may not get back the money you originally invested. The material here is for general information only and is not intended to be relied upon for individual investment decisions. Take independent advice before making such decisions. This site is aimed at UK residents only. To read more please see our Important Warning
-IC-1.5.4a-prod - 31/10/2008 13:11:34 - carlos.princz
